Drugmakers deepen efforts to tap into booming market for obesity drugs – CTV
Feb. 6, 2024
Novo Nordisk’s parent acquired contract drug manufacturer Catalent on Monday, as part of the Danish drugmaker’s efforts to boost production of its obesity drug Wegovy when competition is heating up.
Novo Nordisk and Eli Lilly are so far the leaders in the weight-loss drug market, estimated to be worth US$100 billion by the end of the decade, with their powerful new drugs Wegovy and Zepbound, respectively.
The following is a list of publicly listed companies targeting the next big blockbuster opportunity:
Novo Nordisk said a large study had shown its highly effective obesity drug, Wegovy, also had a clear cardiovascular benefit. Wegovy, which uses the same active ingredient as Novo’s diabetes drug Ozempic, was approved in 2021.
